{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:16:19Z","timestamp":1779297379874,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016087"],"award-info":[{"award-number":["P30 CA016087"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA225450"],"award-info":[{"award-number":["P50 CA225450"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA198495"],"award-info":[{"award-number":["R21 CA198495"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32 AR064184"],"award-info":[{"award-number":["T32 AR064184"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006784","name":"Golfers Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jid.2022.03.031","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T20:27:58Z","timestamp":1650659278000},"page":"2733-2743.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2122-5367","authenticated-orcid":false,"given":"Gregory A.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-0098","authenticated-orcid":false,"given":"Eric","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-2299","authenticated-orcid":false,"given":"Jennifer M.","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-4429","authenticated-orcid":false,"given":"Yilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4552-1825","authenticated-orcid":false,"given":"Jyothirmayee S.","family":"Tadepalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-8754","authenticated-orcid":false,"given":"Christine N.","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-1982","authenticated-orcid":false,"given":"Farbod","family":"Darvishian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-5651","authenticated-orcid":false,"given":"Russell S.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-4751","authenticated-orcid":false,"given":"Richard","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-6755","authenticated-orcid":false,"given":"Yongzhao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-1971","authenticated-orcid":false,"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-5289","authenticated-orcid":false,"given":"David","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.03.031_bib1","first-page":"93","article-title":"The Eight Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jid.2022.03.031_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ijc.31780","article-title":"TERT promoter mutation subtypes and survival in stage I and II melanoma patients","volume":"144","author":"Andr\u00e9s-Lencina","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2022.03.031_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: a common path to immortality","volume":"14","author":"Bell","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jid.2022.03.031_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11910-018-0825-7","article-title":"When the ends are really the beginnings: targeting telomerase for treatment of GBM","volume":"18","author":"Bollam","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jid.2022.03.031_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.03.031_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.euf.2017.09.008","article-title":"Characterization and impact of TERT promoter region mutations on clinical outcome in renal cell carcinoma","volume":"5","author":"Casuscelli","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.jid.2022.03.031_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.01.027","article-title":"TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors","volume":"140","author":"Chang","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.031_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jid.2022.03.031_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jmoldx.2018.09.003","article-title":"Development of novel mutation-specific droplet digital PCR assays detecting TERT promoter mutations in tumor and plasma samples","volume":"21","author":"Corless","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jid.2022.03.031_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gene.2012.01.095","article-title":"Regulation of the human catalytic subunit of telomerase (hTERT)","volume":"498","author":"Daniel","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.jid.2022.03.031_bib11","doi-asserted-by":"crossref","first-page":"589929","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT-regulation and roles in cancer formation","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2022.03.031_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jid.2022.03.031_bib13","doi-asserted-by":"crossref","first-page":"103288","DOI":"10.1016\/j.critrevonc.2021.103288","article-title":"TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis","volume":"160","author":"Gandini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jid.2022.03.031_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0b013e32834e6aa0","article-title":"Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model","volume":"22","author":"Greenwald","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2022.03.031_bib15","doi-asserted-by":"crossref","first-page":"dju246","DOI":"10.1093\/jnci\/dju246","article-title":"TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Griewank","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jid.2022.03.031_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080354","article-title":"TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"8","author":"Griewank","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.03.031_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"Griewank","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2022.03.031_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/modpathol.2013.168","article-title":"TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas","volume":"27","author":"Griewank","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jid.2022.03.031_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.031_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","article-title":"TERT promoter mutations in telomere biology","volume":"771","author":"Heidenreich","year":"2017","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.jid.2022.03.031_bib21","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma","volume":"5","author":"Heidenreich","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2022.03.031_bib22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2006.02.014","article-title":"Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter--effect on telomerase expression and telomere length maintenance in non-small cell lung cancer","volume":"42","author":"Hsu","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2022.03.031_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jid.2022.03.031_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/0008-5472.CAN-10-1588","article-title":"hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells","volume":"71","author":"Indran","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2022.03.031_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.6331","article-title":"The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer","volume":"7","author":"Ko","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2022.03.031_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jnci\/djy086","article-title":"Primary melanoma histologic subtype: impact on survival and response to therapy","volume":"111","author":"Lattanzi","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jid.2022.03.031_bib27","article-title":"Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2022.03.031_bib28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ncb3240","article-title":"Non-canonical NF-\u03baB signalling and ETS1\/2 cooperatively drive C250T mutant tert promoter activation","volume":"17","author":"Li","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jid.2022.03.031_bib29","doi-asserted-by":"crossref","first-page":"36990","DOI":"10.1038\/srep36990","article-title":"TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a metaanalysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2022.03.031_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/genes7070038","article-title":"Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications","volume":"7","author":"Liu","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jid.2022.03.031_bib31","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jid.2022.03.031_bib32","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.18632\/oncotarget.4389","article-title":"TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma","volume":"6","author":"Mosrati","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2022.03.031_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.30042","article-title":"TERT promoter mutations in melanoma survival","volume":"139","author":"Nagore","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2022.03.031_bib35","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1002\/cam4.2467","article-title":"Spectrum of tert promoter mutations and mechanisms of activation in thyroid cancer","volume":"8","author":"Panebianco","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2022.03.031_bib36","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","article-title":"Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup","volume":"26","author":"Pirker","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2022.03.031_bib37","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/jid.2011.451","article-title":"Histology-specific microRNA alterations in melanoma","volume":"132","author":"Poliseno","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.031_bib38","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.03.031_bib39","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-013-1198-2","article-title":"TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma","volume":"126","author":"Remke","year":"2013","journal-title":"Acta neuropathol"},{"key":"10.1016\/j.jid.2022.03.031_bib40","doi-asserted-by":"crossref","first-page":"101543","DOI":"10.1016\/j.redox.2020.101543","article-title":"Non-canonical functions of telomerase reverse transcriptase - impact on redox homeostasis","volume":"34","author":"Rosen","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.jid.2022.03.031_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ajpath.2014.11.021","article-title":"RSK1 activation promotes invasion in nodular melanoma","volume":"185","author":"Salhi","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2022.03.031_bib42","doi-asserted-by":"crossref","first-page":"635488","DOI":"10.3389\/fonc.2021.635488","article-title":"Cutaneous melanoma classification: the importance of high-throughput genomic technologies","volume":"11","author":"Scatena","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2022.03.031_bib43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jid.2019.06.149","article-title":"Classifying melanoma by TERT promoter mutational status","volume":"140","author":"Shaughnessy","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.031_bib44","doi-asserted-by":"crossref","first-page":"50864","DOI":"10.18632\/oncotarget.15140","article-title":"Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2022.03.031_bib45","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1038\/s41388-021-01894-3","article-title":"Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression","volume":"40","author":"Sherman","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2022.03.031_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/nov010","article-title":"Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis","volume":"17","author":"Spiegl-Kreinecker","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jid.2022.03.031_bib47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Spiegl-Kreinecker","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jid.2022.03.031_bib48","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1101\/gad.269498.115","article-title":"Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers","volume":"29","author":"Stern","year":"2015","journal-title":"Genes Dev"},{"key":"10.1016\/j.jid.2022.03.031_bib49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jid.2022.03.031_bib50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma [published correction appears in JAMA Oncol 2015;1:285","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jid.2022.03.031_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.013","article-title":"TERT promoter mutation and its interaction with IDH mutations in glioma: combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-a meta-analysis of aggregate data","volume":"120","author":"Vuong","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jid.2022.03.031_bib52","first-page":"35","article-title":"Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research","volume":"1","author":"Wich","year":"2009","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jid.2022.03.031_bib53","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3390\/ijms21103535","article-title":"Current molecular markers of melanoma and treatment targets","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2022.03.031_bib54","article-title":"Tert promoter mutations\u00a0are enriched in oral cavity cancers and associated with\u00a0locoregional recurrence","volume":"5","author":"Yu","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jid.2022.03.031_bib55","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2022.03.031_bib56","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41379-021-00848-0","article-title":"TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma","volume":"34","author":"Zhang","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:31:04Z","timestamp":1758303064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X22003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022202X22003049"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.031","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}